EmVenio Research and TrialHub Announce Partnership
EmVenio Research has announced a partnership with TrialHub. Through TrialHub's data intelligence gathering platform, EmVenio can identify optimal markets to attract clinical trial participants who are needed to support pharmaceutical sponsors and clinical research organizations' participation goals.
TrialHub's benchmarking and data provide a feasibility overview of the clinical research landscape, allowing EmVenio to strategically select clinical trial site locations based on disease prevalence, recruitment rates, and access to readily available healthcare facilities and practitioners, including underserved communities.
By working with TrialHub, EmVenio will donate a full patient scholarship to the European Patients' Academy on Therapeutic Innovation's Patient Expert program. EUPATI's program focuses on education, inclusivity and stakeholder partnership to enhance patient engagement through accessible and innovative education.
Reference
EmVenio Research and TrialHub partner to optimize patient participation and accelerate site selection for clinical trials. (2023, July 27). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
